The development of standardized case definitions and guidelines for adverse events following immunization
Katrin Kohl(Centers for Disease Control and Prevention), S. Michael Marcy(Kaiser Foundation Hospital), Ulrich Heininger(University Children’s Hospital Basel), Jan Bonhoeffer(University Children’s Hospital Basel), Philippe Duclos(World Health Organization), Bakary Drammeh(Centers for Disease Control and Prevention), Elisabeth Loupi(Sanofi (France)), Michael Buettcher(University of Lucerne), Brigitte Keller‐Stanislawski(Paul Ehrlich Institut), Robert T. Chen(The Task Force for Global Health), Erik Hummelman(Centers for Disease Control and Prevention), Thomas Jefferson, Jane Gidudu(The Centers), M. Miles Braun(Center for Biologics Evaluation and Research), Harald Heijbel(Swedish Institute)
Cited by 86
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
|Journal of Allergy and Clinical Immunology|2006|2.3k
Second Symposium on the Definition and Management of Anaphylaxis: Summary Report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium
|Annals of Emergency Medicine|2006|747
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459